Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer

Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer

(1) Background: Understanding how advanced cancers evade host innate and adaptive immune opponents has led to cancer immunotherapy. Among several immunotherapeutic strategies, the reversal of immunosuppression mediated by regulatory T cells in the tumor microenvironment (TME) using blockers of immun...

Full description

Bibliographic Details
Main Authors:	Kodchakorn Mahasongkram, Kantaphon Glab-ampai, Kanasap Kaewchim, Thanatsaran Saenlom, Monrat Chulanetra, Nitat Sookrung, Oytip Nathalang, Wanpen Chaicumpa
Format:	Article
Language:	English
Published:	MDPI AG 2023-12-01
Series:	Vaccines
Subjects:	cancer immunotherapy bivalent scFvs-Fcγ antibodies fusion protein human single-chain antibody OX40 OX40 agonistic antibodies
Online Access:	https://www.mdpi.com/2076-393X/11/12/1826

Similar Items

Human super antibody to viral RNA-dependent RNA polymerase produced by a modified Sortase self-cleave-bacteria surface display system
by: Kantaphon Glab-ampai, et al.
Published: (2023-12-01)

Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies
by: Kanasap Kaewchim, et al.
Published: (2023-05-01)

Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms
by: Marianne Bachmann Salvy, et al.
Published: (2024-12-01)

Correction: Kaewchim et al. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. <i>Viruses</i> 2023, <i>15</i>, 1252
by: Kanasap Kaewchim, et al.
Published: (2023-09-01)

A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab
by: Asaad Abdelhalim, et al.
Published: (2024-11-01)

OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab
by: Ana Maria Lé, et al.
Published: (2022-12-01)

Engineered Fully Human Single-Chain Monoclonal Antibodies to PIM2 Kinase
by: Kanasap Kaewchim, et al.
Published: (2021-10-01)

Structural Basis of a Novel Agonistic Anti-OX40 Antibody
by: Jing Zhang, et al.
Published: (2022-08-01)

Integrating In Silico and In Vitro Tools for Optimized Antibody Development—Design of Therapeutic Anti-oxMIF Antibodies
by: Gregor Rossmueller, et al.
Published: (2024-12-01)

Relationship between bladder cancer and polymorphisms of OX40 (rs17568) and OX40L (rs1234313) genes in a Turkish population
by: Osman Bilen, et al.
Published: (2023-03-01)

An OX-Tra’Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis
by: Kaviyon Sadrolashrafi, et al.
Published: (2024-03-01)

BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy
by: Shizhong Liang, et al.
Published: (2023-07-01)

The state of the art of bispecific antibodies for treating human malignancies
by: Shuhang Wang, et al.
Published: (2021-08-01)

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis
by: Barbara Rewerska, MD, et al.
Published: (2024-02-01)

Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes
by: Ayaka Sato, et al.
Published: (2025-01-01)

The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial
by: Ronit Shiri-Sverdlov, et al.
Published: (2021-01-01)

Novel Neutralizing Epitope of PEDV S1 Protein Identified by IgM Monoclonal Antibody
by: Techit Thavorasak, et al.
Published: (2022-01-01)

Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection
by: Monrat Chulanetra, et al.
Published: (2024-11-01)

Engineered Human Monoclonal scFv to Receptor Binding Domain of <i>Ebolavirus</i>
by: Jaslan Densumite, et al.
Published: (2021-05-01)

An Engineered Influenza a Virus Expressing the Co-Stimulator OX40L as an Oncolytic Agent Against Hepatocellular Carcinoma
by: Yang H, et al.
Published: (2024-01-01)

Caecum OX40+CD4 T-cell subset associates with mucosal damage and key markers of disease in treated HIV-infection
by: Isaac Rosado-Sánchez, et al.
Published: (2023-12-01)

بررسی سطح سرمی OX40 در بیماران مبتلا به نورومیلیت اپتیکا در مقایسه با افراد سالم
by: Paria Alidadiani, et al.
Published: (2016-08-01)

Effects of Huang-Lian-Jie-Du decoction on improving skin barrier function and modulating T helper cell differentiation in 1-chloro-2,4-dinitrobenzene-induced atopic dermatitis mice
by: Huiyuan Zhang, et al.
Published: (2024-11-01)

OX40 (CD134) Expression on T Regulatory Cells Is Related to Serious Hypertensive Disorders in Pregnancy
by: Maciej Kwiatek, et al.
Published: (2023-10-01)

OX40 ligand newly expressed on bronchiolar progenitors mediates influenza infection and further exacerbates pneumonia
by: Taizou Hirano, et al.
Published: (2016-03-01)

Association between OX40L polymorphism and type 2 diabetes mellitus in Iranians
by: Abdolreza Sotoodeh Jahromi, et al.
Published: (2024-07-01)

The expression of immune co-stimulators as a prognostic predictor of head and neck squamous cell carcinomas and oral squamous cell carcinomas
by: Shi-Rou Chang, et al.
Published: (2024-07-01)

Curcumin Enhances the Abscopal Effect in Mice with Colorectal Cancer by Acting as an Immunomodulator
by: Kuang-Chung Shih, et al.
Published: (2023-05-01)

Equal Maintenance of Anti-SARS-CoV-2 Antibody Levels Induced by Heterologous and Homologous Regimens of the BNT162b2, ChAdOx1, CoronaVac and Ad26.COV2.S Vaccines: A Longitudinal Study Up to the 4th Dose of Booster
by: Tatiana A. do Nascimento, et al.
Published: (2024-07-01)

A multifunctional targeted nano-delivery system with radiosensitization and immune activation in glioblastoma
by: Xin Wen, et al.
Published: (2024-09-01)

Fundamental Characterization of Antibody Fusion-Single-Chain TNF Recombinant Proteins Directed against Costimulatory TNF Receptors Expressed by T-Lymphocytes
by: Hodaka Nagai, et al.
Published: (2023-06-01)

An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
by: Josue Antonio Estrada, et al.
Published: (2022-04-01)

IL-33-primed human mast cells drive IL-9 production by CD4+ effector T cells in an OX40L-dependent manner
by: Louise Battut, et al.
Published: (2024-10-01)

Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy
by: Zhichen Sun, et al.
Published: (2023-09-01)

Activation of OX40 and CD27 Costimulatory Signalling in Sheep through Recombinant Ovine Ligands
by: José Manuel Rojas, et al.
Published: (2020-06-01)

Recombinant Costimulatory Fusion Proteins as Functional Immunomodulators Enhance Antitumor Activity in Murine B16F10 Melanoma
by: Huaman Cai, et al.
Published: (2020-05-01)

Elevation of the Plasma Levels of TNF Receptor 2 in Association with Those of CD25, OX40, and IL-10 and HTLV-1 Proviral Load in Acute Adult T-Cell Leukemia
by: Megumi Kato, et al.
Published: (2022-04-01)

Synovial Macrophages Expression of OX40L Is Required for Follicular Helper T Cells Differentiation in the Joint Microenvironment
by: Xiaoyu Cai, et al.
Published: (2022-10-01)

Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments
by: Suzanne I. Sitnikova, et al.
Published: (2023-10-01)

Comparative study of neutralizing antibodies titers in response to different types of COVID-19 vaccines among a group of egyptian healthcare workers
by: Sara Maher, et al.
Published: (2024-11-01)